Major news, missed this one…14 Dec 2021 10:53
the clinical study was a major milestone: "We are encouraged by the trial findings which indicate that AZD1656, a simple oral tablet, has the potential to become a new treatment for COVID-19 - independent of viral mutations - initiating a new wave of therapies for clinicians in meeting this global challenge."
James Normand, director of Vela, said: "The board of Vela is delighted to be informed of this significant development in what is the company's most material investment. We note that St George Street is now moving forward with the proposed commercialisation of the AZ1656 drug and we look forward to positive news on this process in the near future."